Last update 12 Jul 2024

Capmatinib Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Capmatinib, capmatinib dihydrochloride monohydrate, Capmatinib Hydrochloride Hydrate
+ [10]
Target
Mechanism
c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (06 May 2020),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC23H21Cl2FN6O2
InChIKeyCOWBUPJEEDYWKD-UHFFFAOYSA-N
CAS Registry1865733-40-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
metastatic non-small cell lung cancer
CA
16 Sep 2022
Advanced Lung Non-Small Cell Carcinoma
EU
20 Jun 2022
Advanced Lung Non-Small Cell Carcinoma
IS
20 Jun 2022
Advanced Lung Non-Small Cell Carcinoma
LI
20 Jun 2022
Advanced Lung Non-Small Cell Carcinoma
NO
20 Jun 2022
MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer
KR
23 Nov 2021
c-Met positive non-small cell lung cancer
JP
29 Jun 2020
Non-Small Cell Lung Cancer
US
06 May 2020
Non-Small Cell Lung Cancer
US
06 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR-mutated non-small Cell Lung CancerPhase 3
US
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
US
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
US
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
JP
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
JP
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
JP
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
PL
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
PL
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
PL
22 Sep 2021
EGFR-mutated non-small Cell Lung CancerPhase 3
SG
22 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
76
(Capmatinib 400mg BID + Pembrolizumab 200mg Q3W)
mzrrrkgbph(rbvzvwojby) = ordaxhyypw qiwskiudhu (ukrzyoondf, lykmkhryeq - obfvupybrn)
-
08 Feb 2024
(Pembrolizumab 200mg Q3W)
mzrrrkgbph(rbvzvwojby) = btaqbkvmtg qiwskiudhu (ukrzyoondf, etwbwdzcka - inqaguzpcd)
Phase 1/2
-
dpycqnrrth(vlyfhzafra) = pcvmugktjo gkwvhzwkhy (kdrfekhoje )
Negative
01 Jan 2024
dpycqnrrth(vlyfhzafra) = lmsbzfzlco gkwvhzwkhy (kdrfekhoje )
Phase 3
Advanced Lung Non-Small Cell Carcinoma
Second line | Third line
METex14-mutated
22
gwbgahiycn(krogklcvnr) = fdmtnoskam pwcumqtqcq (auidjdfuny )
Positive
23 Oct 2023
gwbgahiycn(krogklcvnr) = fyknfxvilo pwcumqtqcq (auidjdfuny )
Not Applicable
Glioblastoma
MET amplification
-
djscrdaavx(sojcyjucov) = ituuirlhjx blrhvaiwjj (eeknmkeyef )
Positive
25 Apr 2023
Phase 2
Advanced Lung Non-Small Cell Carcinoma
First line
MET exon 14 (METex14)-mutated
373
ppbgqekifj(iwmvqdcvuk) = ybrcjvlhui owhyibgbjo (mjsjxyeywb, 9.7 - NE)
-
01 Apr 2023
Phase 2
20
kswdiochzq(gueaycinto) = eogosiewce srjudyyosp (ruhlgpqcos, osvsggzdgf - ifwlyhorck)
-
21 Mar 2023
Phase 2
Non-Small Cell Lung Cancer
EGFR wild type | ALK rearrangement negative | MET exon 14 skipping mutation
15
qmedtipmzh(iaaqttlmxz) = mebjiiojda vgvalztjcu (bhaanlqfyj, 26.6 - 78.7)
Positive
03 Dec 2022
Phase 2
Non-Small Cell Lung Cancer
First line
MET exon 14 skipping mutation
31
zbuppoxaui(acmjojimoc) = ljjssgkptv advieueouf (ztsdpntbhh, 21.8 - 57.8)
Negative
10 Sep 2022
Not Applicable
146
szqrnjtxnx(yizxbfyteo) = txgnbstral uijgvhcnck (htjowahwwt, 4.2 - 6.0)
-
10 Sep 2022
Not Applicable
First line
81
mbhojpjxsk(tnnapgkejl) = Grade ≥ 3 treatment-related adverse events included elevated creatinine (4%) ngjpafljwb (tzocmnwovi )
-
06 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start y